Healthcare / BiotechnologyKOSDAQ
$40800.00
-1350.00 (-3.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-7.5B · quality 63.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$540.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-12.4%
↓Gross Margin
65.8%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+82.1%
FCF CAGR
—
FCF margin
-66.6%
FCF / Net income
1.57x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $11.31B · net income $-4.81B · FCF $-7.53B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $11.31B | $11.31B | $5.94B | $3.75B | $1.87B |
| Net Income | $-4.81B | $-4.81B | $-8.30B | $-23.55B | $29.34B |
| EBITDA | $-3.22B | $-3.22B | $-7.01B | $-17.31B | $34.39B |
| EPS | -365.00 | -365.00 | -754.00 | -5158.00 | -559.00 |
| Gross Margin | 65.8% | 65.8% | 60.4% | 58.2% | 50.4% |
| Operating Margin | -49.3% | -49.3% | -147.8% | -179.5% | -340.4% |
| Net Margin | -42.5% | -42.5% | -139.8% | -628.5% | 1567.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.00 | 0.06 | -0.05 |
| Current Ratio | 19.23 | 19.23 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-7.53B | $-7.53B | $-7.47B | $-6.16B | $-7.32B |
| Returns | |||||
| ROE | -12.4% | -12.4% | -19.8% | -133.0% | -105.4% |
| Valuation | |||||
| P/B | 13.86 | 13.86 | 4.23 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 90.4% | 90.4% | 58.5% | 100.3% | — |
| EPS Growth | 51.6% | 51.6% | 85.4% | -822.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+37.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-754.00 → -365.00
Residual
+37.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.